| Objective 1. This study aims to investigate the short-term recuperate effect and prognostic significance of the NF-κB/p65 expression in diffuse large B cell lymphoma(DLBCL) patients treated with RCHOP(rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). 2. To explore NF-κB/p65 expression in the bone marrow of newly diagnosed multiple myeloma(MM) and the relationship between short-term relief after treatment.Methods 1. Immunohistochemistry(IHC) was used to detect the expression of NF-κB/p65 in formalin-fixed paraffin-embedded specimens of 73 newly diagnosed DLBCL patients with the RCHOP chemotherapy. 2. The bone marrow sections were made from plastic(methyl-methacrylate)-embedded bone marrow biopsies. The NF-κB/p65 expression in the bone marrow sections of MM group and normal control group were detected by En Vison immunohistochemistry(IHC). The clinical significance of NF-κB/p65 was analyzed.Results 一〠1. NF-κB/p65 was highly expressed in 27.4%(20/73) DLBCL tumors, and it was highly expressed in GCB DLBCL and non-GCB DLBCL tumors were 12%(3/25) and 35.4%(17/48), respectively. They were statistically significant difference(P<0.05). 2. The complete remission rate after four or six times RCHOP treatment in high and low NF-κB/p65 group were 35% and 58.5%, respectively. It showed nostatistically significance(P=0.073). 3. Analyze the clinical information of 73 newly diagnosed DLBCL patients by Kaplan-Meier method.low IPI score(0-2) was 29 cases,middle and high IPI score(3-5)were 44 cases,2-year OS rate was 89.7% and 72.0%(P=0.002),2-year PFS rate was 82.8% and 54.5%(P<0.0001).but on gender,age,Ann Arbor staging,B syptoms,LDH level and extranodal involvement,there were no statistically difference in OS and PFS(P>0.05). 4. DLBCL cases with high NF-κB/p65 expression showed a significantly poorer overall survival(OS) and progression-free survival(PFS) as compared with those with low NF-κB/p65 expression(55% vs 83%,P=0.0125 and 35% vs 73%,P=0.0051, respectively). In non-GCB phenotype cases, high NF-κB/p65 expression also showed a significantly poorer OS and PFS as compared with low NF-κB/p65 expression(52% vs 83%,P=0.0427 and 35% vs 74%,P= 0.0343, respectively). 5. According to multivariate analysis the NF-κB/p65 expression(OS,P=0.032 and PFS,P=0.005) and IPI(OS,P=0.025 and PFS,P=0.004) were independent factor for both OS and PFS. 二〠1. NF-κB/p65 was highly expressed in 40.67%(24/59) MM bone marrow biopsies. and on age,gender, ISS staging, DS staging, M protein, serum creatinine, hemoglobin, β2-microglobulin and short-term remission rates, NF-κB/p65 shows no statistical difference between the high and low expr- ession(P> 0.05). 2. The cases of high and low NF-κB/p65 expression in MM bone marrow biopsies were 24 and 35,respectively. Expression of all 10 patients in the normal control group were low, there was a significant difference between the two groups(p< 0.05).3. In patients of highly NF-κB/p65 expressed, the short-term remission rate shows statistically significant difference between group treated with bortezomib and group treated without bortezomib(P=0.02), but in patients with low expression of NF-κB/p65, the remission rates shows no significant differences in the two groups(P=0.11).Conclusions 一〠1. This study suggests that the NF-κB/p65 expression is an important inferior prognostic factor for survival in patients with DLBCL treated with RCHOP. 2. Especially in non-GCB phenotype cases need to be individualized treatment in order to improve the long-term recuperate effect. 二〠1. The NF-κB/p65 expression in MM bone marrow biopsies were significantly increased, maybe it’s involved in the pathogenesis of MM. 2. Blocking the activation of NF-κB pathway is one of the mechanism of bortezomib, for MM patients with high expression of NF-κB/p65, preferred the clinical benefit of bortezomib- based regimens, and improve treatment efficacy.
|
PDF Full Text Request